Jobs / United States / Regeneron Pharmaceuticals INC
Director Therapeutic Area Genetics (Oncology)
Regeneron Pharmaceuticals INC · 🇺🇸 TARRYTOWN
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Regeneron Pharmaceuticals INC paid sponsored hires in similar roles13 certified filings for “Associate Director Imaging” (Natural Sciences Managers) in NY: $201k–$281k, median $225k. Most were filed at wage level II (69%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Regeneron Pharmaceuticals INC
The US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Regeneron Pharmaceuticals INC →
About the role
Build our future together: We are seeking an exceptional senior leader with deep expertise in cancer genetics and genomics to join our team at the Regeneron Genetics Center. This Director-level role carries full accountability for the strategy and execution of cancer genetic product development — from aligning the vision with senior leadership and translating it into an actionable operational plan, through overseeing product development and setting the strategy for commercialization. The ideal candidate will bring a demonstrated track record of independence and impact, and will serve as the driving force for bringing cancer risk genomics into clinical and commercial reality. When & where: • Location: Tarrytown, NY • Work model/flexibility: 4 days onsite Discover your role: • Develop and deliver on cancer genetics testing opportunities, including germline testing partnerships, serving as the senior leader accountable for clinical cancer test development. • Define and own the end-to-end strategy for germline genetic cancer risk product development, translating organizational vision — aligned with senior leadership — into a clear, actionable operational roadmap with measurable milestones. • Develop and execute a comprehensive somatic genetics strategy for Regeneron’s oncology portfolio, identifying new opportunities for somatic profiling studies across tumor types and leveraging existing cancer genomics databases. • Lead and execute large-scale somatic cancer sequencing analyses, including whole-exome and whole-genome sequencing of tumor samples, RNA-seq, and integrative multi-OMICS studies to identify driver mutations, therapeutic vulnerabilities, and mechanisms of resistance. • Design and contribute to cancer molecular profiling and clinical correlation analyses that integrate germline and somatic mutational profiles with multi-modal transcriptomic, epigenetic, and proteomic data to support target discovery, indication selection, and patient stratification strategies. • Oversee all phases of product development for cancer risk genomics programs, ensuring scientific rigor, cross-functional alignment, and on-time delivery against strategic objectives. • Develop and execute the commercialization strategy for RGC cancer products, identifying market opportunities, go-to-market pathways, and partnerships that maximize clinical and commercial impact. • Collaborate with and lead a multidisciplinary genetics team consisting of human genetics scientists, bioinformaticians, and statistical geneticists to design, execute, and interpret genetics studies related to cancer risk, somatic evolution, mechanisms, and therapeutic outcomes. This role requires: • MD or MD/PhD with a strong background in quantitative biology applied to cancer genetics and genomics, and a proven ability to design and lead large-scale human cancer genomic programs delivering medically- and commercially-relevant outcomes. • 12 years of research experience in cancer genetics, genomics, or oncology product development is required, with a commensurate level of independence, seniority, and demonstrated responsibility for program strategy and execution. • Demonstrated ability to independently own and drive strategic programs in cancer risk genomics or oncology product development from conception through commercialization. • Bring innovative thinking and hands-on leadership to large-scale somatic cancer sequencing studies and integrative genomic analyses. • Have deep expertise in analyzing tumor sequencing data, including variant calling, mutational signature analysis, clonal evolution, copy number alterations, and structural variant detection. • Have experience in developing or contributing to germline diagnostic tests for cancer predisposition, risk as